US biotech major Gilead Sciences (Nasdaq: GILD) has halted two mid-stage studies of its experimental antiviral obeldesivir after low rates of respiratory syncytial virus (RSV) infections undermined the feasibility of measuring symptom relief in patients.
The trials, focused on outpatient adults and children with acute RSV, were called off after what the company described as a challenging season for patient recruitment. Gilead said the studies failed to gather sufficient data to meaningfully assess the primary endpoint, which was the reduction in symptom duration.
The move does not stem from any safety or efficacy issues, according to the company, which plans to share results from the discontinued studies in due course to help evaluate future possibilities for the oral antiviral.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze